Review Article

JOURNAL OF DRUG REACTIONS
An international online peer reviewed, open access Journal
Content available at www.cognixpress.in Online ISSN: 3139-4132

MONOCLONAL ANTIBODIES – BASED CANCER THERAPEUTICS :CURRENT STRATEGIES, RESISTANCE, MECHANISMS, FUTURE PERSPECTIVE

UPPALAPATI LEELA KRISHNA*, G NAGARAJU, BUDAGALA GAYATHRI, CHANDU BABU RAO

Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

***Corresponding Author**
Uppalapati Leela krishna

Article History: 22.04.2026 Received: 03.05.2026 Revised: Accepted: 16.06.2026

ABSTRACT
Monoclonal antibodies(mAbs) have revolutionized oncology by offering largely specific remedial options that target tumour associated antigens, minimizing damage to healthy apkins. These biologics ply their goods through colorful mechanisms including receptor leaguer, vulnerable system modulation, induction of apoptosis, and targeted delivery of cytotoxic agents. The development of coming- generation antibody formats similar as bispecific antibodies, antibody-medicine conjugates(ADCs), nanobodies, and emulsion proteins has further enhanced their efficacity and broadened clinical operations. likewise, advances in artificial intelligence(AI) and bioinformatics are paving the way for individualized antibody- grounded curatives acclimatized to individual tumour biographies. Despite their growing clinical mileage, mAb-grounded curatives face several challenges that limit their broader perpetration. These include excrescence diversity, development of resistance pathways, vulnerable elusion tactics by cancer cells, limited tumour penetration, and high manufacturing costs. also, adverse goods similar as cytokine release pattern and immunogenicity present further clinical hurdles. This review provides a comprehensive overview of monoclonal antibody mechanisms of action, current remedial strategies, arising inventions, and the crucial natural and logistical challenges encountered in their development and use. unborn directions punctuate the integration of computational tools for antibody design, combination curatives with vulnerable checkpoint impediments, and strategies to ameliorate global access and affordability.

Keywords: *Monoclonal Antibodies; Cancer Immunotherapy; Bispecific Antibodies; Antibody- medicine Conjugates; Tumour Microenvironment; Personalized Medicine; Artificial Intelligence in Oncology.*

1.INTRODUCTION

Antibodies have come a foundation of cancer immunotherapy, offering a targeted approach to combat tumours [1]. Monoclonal antibodies(moAbs or mAbs) are produced to honor antigens expressed on tumour cells, enabling precise intervention with minimum impact on healthy apkins [2]. These curatives work through colorful mechanisms, including vulnerable system activation, inhibition of tumour growth, and delivery of cytotoxic agents [3]. A well- established operation of antibodies is vulnerable checkpoint leaguer. Antibodies targeting " Programmed Cell Death Protein- 1(PD- 1), Programmed Cell Death Ligand-1(PD- L1), and Cytotoxic T-Lymphocyte- Associated Protein 4(CTLA-4) " restore T-cell exertion, allowing the vulnerable system to identify and destroy tumours [4]. Another advanced strategy involves antibody -medicine conjugates (ADCs), which integrate the perfection of antibodies with the energy of cytotoxic agents. By directing these medicines specifically to cancer cells, ADCs reduce off-target good [5].Bispecific antibodies, designed to engage two different antigens contemporaneously, are also gaining elevation. For illustration, bispecific T-cell engagers(mouthfuls) like blinatumomab bring lymphocyte T into close propinquity to tumour cells, easing vulnerable- mediated destruction [6]. Monoclonal antibodies stepped into the spotlight in the early 1980s. In 1986, the monoclonal antibody named Ortho clone OKT3 was approved for the forestallment of graft rejection in cases who had entered order transplantation [7].

Targeted antigens include : A. Surface antigens, which are proteins on the face of cancer cells that mAbs attach to, similar as HER2 in bone cancer(e.g., trastuzumab) Intracellular antigens : These antigens target proteins inside cancer cells and must be internalized in order to have a remedial impact [8].

2. ANTIBODY STRUCTURE AND FUNCTION

Y-shaped proteins called antibodies, also known as immunoglobulins, are essential to the immune system's operation [9]. Antibodies, which consist of two heavy and two light polypeptide chains joined by disulfide bonds, display certain regions:Area of Variability(Fab) Antigen binding point : set up at the ends of the Y, this point precisely identifies and binds particular antigen [10]. Diversity : The capability of antibodies to fete a broad variety of antigens is made possible by variable disciplines in the heavy and light chain. Constant Region(FC) Effector Functions : Establishes the class of the antibody(IgG, IgA, IgM, IgD, or IgE) and mediates effector conduct similar complement system commerce and vulnerable cell activation [11]. Structure Stability : Preserves the antibody's structural integrity. Antibodies operate via multiple mechanisms.

3. PHAGE DISPLAY TECHNOLOGY IN DEVELOPMENT OF THERAPEUTIC ANTIBODY

Human antibodies are the most favored bone for patient care which can be generated in transgenic creatures, generally mice or rat, using hybridoma technology after introducing the mortal immunoglobulin loci while knocking down their own counterpart. To exclude the necessity of edging in the antigen in creatures, phage dis play technology, discovered in 1985 by George P. Smith, was exploited as in- vitro antibody selection system by Sir George P Winter which gave the honor of easy access to the coding sequence of the antibody for farther manipulation. For the discovery of this elegant system of producing medicinals, George P. Smith and Sir George P. Winter participated one- half of the 2018 Nobel Prize in Chemistry. The first mortal antibody Adalimumab(Humira) using phage display technology was approved in USA in 2002 for the treatment of arthritis and Crohn's complaint which inactivates excrescence necrosis factor- nascence(TNF- α) [12,13].

4.MMUNOMODULATORY APPROACHES AND CHECK PATHWAY

Immune Checkpoint Pathway : The vulnerable checkpoint pathway plays a vital part in controlling vulnerable responses, precluding overactivity, and maintaining tone- forbearance(26). still, cancer cells exploit these mechanisms to avoid destruction by the vulnerable system [14]. Crucial checkpoints, similar as CTLA- 4 and PD- 1, serve as major controllers in this process [15]. Their activation suppresses T- cell function, allowing tumour cells to gain without restraint [16].

Medium of Action :Immune checkpoint impediments block the commerce between checkpoint proteins and their ligands(e.g., PD- 1/ PD- L1, CTLA- 4/ B7), restoring T- cell exertion and enabling the vulnerable system to honor and attack tumour cells [17]. still, ongoing exploration focuses on prostrating resistance and expanding suggestions through combination curatives [18]. " CTLA- 4 impediments(e.g., ipilimumab) block the commerce between CTLA- 4 and its ligands B7- 1/ B7- 2 on antigen- presenting cells ", easing T- cell activation [19].

5.MECHANISM OF ACTON USE OF BISPECIFIC ANTIBODIES AND T CELL ENGAGERS

Bispecific Antibodies(BsAbs) :

- Definition Engineered antibodies with binary particularity-each arm binds a different antigen. • Medium One arm bind to a excrescence antigen; the other engages vulnerable effector cells(like CD3 on T- cells), turning them to kill cancer cells.
- Example Blinatumomab targets CD19(on B- cells) and CD3(on T- cells) in B- cell leukaemia.
- Advantages bettered vulnerable activation, precise targeting, and reduced escape eventuality.

T cell engagers : The action of T- cell engagers (TCEs), a type of bispecific antibodies. It involves their binary- list capability, as they attach to tumour- associated antigens (TAAs) and CD3 receptors. This binary commerce facilitates the establishment of a cytolytic synapse.

6. ANTIBODY – DRUG CONJUGATES(ADCS) WITH IMMUNE MODIFICATION

description Monoclonal antibodies chemically linked to potent cytotoxic medicines.

Medium The mAb binds to the excrescence cell, is internalized, and releases the cytotoxic medicine directly into the excrescence, limiting damage to normal cells.

Example Trastuzumab emtansine (T- DM1) for HER2-positive bone cancer.

converting Immunogenic Cell Death(ICD) Some ADC loads, similar as microtubule impediments (e.g., MMAE) or DNA- damaging agents.

Targeting the Tumour Microenvironment(TME) Some ADCs are designed to deplete nonsupervisory T cells (Tregs) or myeloid- deduced suppressor cells (MDSCs), by targeting specific labels like CD25 or CCR8.

7. RECEPTOR- TARGETED THERAPIES:(HER2, EGFR INHIBITORS)

HER2 Inhibition and Receptor Tyrosine Kinase motioning: is a receptor tyrosine kinase involved in regulating cell growth, survival, and isolation [20].

Overexpression or modification of HER2 is generally observed in aggressive cancers, including gastric can cancer cell death [21].

The epidermal growth factor receptor (EGFR) family also comprises HER2, which activates critical intracellular signalling pathways. Upon dimerization with other EGFR Targeting the Tumour Microenvironment(TME) Some ADCs are designed to deplete nonsupervisory T cells (Tregs) or myeloid- deduced suppressor cells (MDSCs), by targeting specific labels like CD25 or CCR8; 3. family members, HER2 triggers falls similar as the PI3K- AKT pathway (promoting cell survival and inhibiting apoptosis), the RAS- RAF- MEK- ERK pathway.

8.TARGETTING ANGIOGENESIS VEGF PATHWAY

Targeting Angiogenesis in Cancer VEGF/ VEGFR Pathway Angiogenesis plays a abecedarian part in cancer growth and progression. Tumours exploit this process to establish a blood force, icing the delivery of oxygen and nutrients essential for their expansion and metastasis. The vascular endothelial growth factor(VEGF) signalling pathway, which involves VEGF and its receptor VEGFR, is a crucial controller of angiogenesis [22]. Angiogenesis and the VEGF/ VEGFR Pathway :he VEGF family comprises several ligands, including VEGF- A, VEGF- B, VEGF- C, and VEGF- D, which interact with VEGFRs - specifically VEGFR- 1, VEGFR- 2, and VEGFR 3 -on endothelial cells. Among these, VEGF- A is the primary motorist of tumour- convinced angiogenesis. When VEGF- A binds to VEGFR- 2, it triggers downstream signalling falls similar as PI3K/ AKT and MAPK, promoting endothelial cell proliferation, migration, and the conformation of new blood vessels [23].

9. EMERGING TUMOUR CELL SURFACE MARKER

Trop- 2 is a protein set up in high quantities on the face of certain cancer cells, including those in bone, bladder, lung, and stomach cancers. It supports tumour growth by helping cells multiply, spread, and avoid death. This makes it a useful target for treatments tha deliver poisonous medicines directly to cancer cells.

Sacituzumab govitecan(Trodelvy) is an FDA- approved antibody -medicine conjugate(ADC) designed to target Trop- 2, a protein that's constantly overexpressed in multiple cancers. Regulatory blessing has been granted for its use in treating.[24]Locally advanced or metastatic urothelial melanoma Approved in 2021 for cases who have been preliminarily treated with platinum- grounded chemotherapy and a PD- 1/ PD- L1 asset.

10. MUCOSAL SURFACE TUMOUR AND IGE ANTIBODY THERAPY

IgA antibodies are essential for immune defence at mucosal surfaces, including the respiratory, gastrointestinal, and urogenital tracts. They are the first line of defence against pathogens, preventing infections at these sites. Recently, IgA antibodies have gained atten tion in cancer immunotherapy, particularly for targeting mucosal cancers, such as those of the colon, oesophagus, and head and neck. These cancers often arise in areas rich in mu cosal tissues, making IgA antibodies a promising tool for localised therapy. The potential of IgAantibodies in cancer therapy lies in their ability to recognise tumour-associated antigens present on mucosal surfaces. When these antibodies bind to such antigens, they can trigger immune responses at the tumour site, activating mechanisms such as complement acti vation and antibody-dependent cellular cytotoxicity (ADCC). The study's focus on anti-EBV antibody responses could explore how sex differences in IgA levels or activity contribute to the immune system's ability to control or eliminate EBV, a well-known virus directly involved in the immunopathogenesis of several cancers, including those of the head and neck. A stronger or weaker immune response could influence susceptibility to EBV-related cancers or affect the progression of existing malignancies. It could also inform howimmunecheckpoint blockade therapies or other immunotherapies might vary by sex in terms of efficacy, particularly in cancers associated with EBV.

11. RESISTANCE MECHANISMS TO MONOCLONAL ANTIBODY THERAPY

remedy resistance can also appear in tumours transitioning phenotypically from epithelial to mesenchymal (EMT) state performing in loss of cell- to-cell contact and come more migrant in nature promoting stem cells characteristicsAntigen Loss or Mutation Excrescence cells may downregulate or genetically alter the target antigen, similar as HER2 or CD20, reducing antibody list and picture remedy ineffective. Activation of Alternative Signalling Pathways Cancer cells can bypass blocked pathways by cranking compensatory falls like PI3K/ AKT or RAS/ RAF/ MEK, maintaining their proliferation and survival despite receptor leaguer.

12. MONOCLONAL ANTIBODIES APPROVED IN THE 2020S

ISATUXIMAB :Isatuximab(also named SAR650984 or Sarclisa ®) is a fantastic IgG1 antibody developed by Immune Gen and Sanofi- Aventis able of targeting CD38. CD38 is a cell face antigen with ectoenzymatic exertion over expressed on nasty tube cells, which are a type of B cells responsible for antibody product and stashing in the body [25]. thus this antigen can be a consider

suitable target in the immunotherapy of multiple myeloma, In March 2020

NAXITAMAB: Naxitamab is a humanized GD2-specific monoclonal antibody (also known as naxitamab-gqgkorhu 3 F8), which in November 2020, was approved for the treatment of cases (≥ 1- time-old) with R/ Neuroblastoma(either in the bone or bone gist), in confluence with GM- CSF, who have preliminarily experienced previous treatments and have responded to it in the form of partial responses, stable dis eases, or indeed minor responses [26].

13. EFFECTS AND SAFETY CHALLENGES

Infusion-Related Reactions (IRRs): Common during initial infusions, especially with chimeric or murine-derived antibodies. Symptoms may include fever, chills, hypotension, rash, and bronchospasm. Cytokine Release Syndrome (CRS): Occurs primarily with T-cell engaging antibodies (e.g., bispecific like blinatumomab). Massive cytokine release can lead to systemic inflammation, organ dysfunction, hypotension, and respiratory distress.

14. NEXT-GENERATION MONOCLONAL ANTIBODIES AND FUTURE DIRECTION

Innovations in antibody engineering have led to next-generation therapies designed to enhance efficacy, reduce toxicity, and overcome resistance.Nanobodies and Fusion Proteins

- Nanobodies: Single-domain antibody fragments derived from camelid heavy-chain-only antibodies. Their small size (~15 kDa) allows deep tissue penetration and excellent stability.
- Example: Caplacizumab, a nanobody targeting von Willebrand factor.
- Fusion Proteins: Combine the Fc region of antibodies with biologically active ligands or enzymes.
- Example: Etanercept, a TNF receptor-Fc fusion protein used in rheumatoid arthritis.
- Benefits: Enhanced bioavailability, prolonged half-life, and targeted activity.
- Personalized Antibody Therapy
- Concept: Tailoring antibody therapies based on individual genomic, proteomic, or transcriptomic tumor profiles.
- Technologies: Use of AI algorithms, B-cell receptor sequencing, and neoantigen prediction to design customized antibodies.

15. FUTURE DIRECTION

The use of monoclonal antibodies (mAbs) to treat cancer will likely require novel ways to improve immunotherapies. Increasing mAb specificity, lowering treatment resistance, and minimizing immune-related side effects,are a few examples of this. Furthermore, creating combination treatments that work well with immune checkpoint inhibitors and targeted therapies in addition to mAbs is becoming increasingly important

16. FUTURE ASPECTS

Recombinant constructs of antibodies targeting multiple antigens at a time (multi-specific antibody) are being developed for better efficacity. piecemeal from anti body. Development of astronomically negativing antibodies (bnAbs) targeting conserved viral epitopes. Establishment of modular mAb platforms for fast reprogramming across conditions. operation in contagion- driven cancers like HPV (cervical cancer) and EBV(nasopharyngeal melanoma).

17. CONCLUSIONS

Monoclonal antibodies (mAbs) have significantly converted cancer remedy by furnishing largely specific, targeted treatment. These laboratory- finagled motes identify and bind to antigens on cancer cells, leading to tumour inhibition through direct cytotoxicity, vulnerable activation, and dislocation of cancer- promoting pathways. A crucial vulnerable- mediated medium of mAbs is antibody-dependent cellular cytotoxicity, where natural killer cells bind to the Fc region of antibody-carpeted cancer cells, driving apoptosis.

18. AUTHOR CONTRIBUTIONS

All authors are contributed equally.

19.FINANCIAL SUPPORT

None

20. DECLARATION COMPETING INTEREST

The authors have no conflicts of interest to declare.

21.ACKNOWLEDGEMENTS

None

22.REFERENCES

1. Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21(15):5510. Available from: https://doi.org/10.3390/ijms21155510
2. Zlabinger GJ, Ulrich W, Pohanka E, Kovarik J. OKT 3-Therapie bei Nierentransplantatempfängern [OKT 3 treatment of kidney transplant recipients]. Wien Klin Wochenschr. 1990;102(5):142-147. Available from: https://pubmed.ncbi.nlm.nih.gov/2108521/
3. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol

Cell Biol. 2015;93(3):290-296. Available from: https://doi.org/10.1038/icb.2014.93
4. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov. 2013;12(4):259-260. Available from: https://doi.org/10.1038/nrd3980
5. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. Available from: https://doi.org/10.1186/s13045-021-01056-8
6. Fatima I, Rahdar A, Sargazi S, Barani M, Hassanisaadi M, Thakur VK. Quantum dots: synthesis, antibody conjugation, and HER2-receptor targeting for breast cancer therapy. J Funct Biomater. 2021;12(4):75. Available from: https://doi.org/10.3390/jfb12040075
7. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-480. Available from: https://doi.org/10.1038/nrc2394
8. Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull. 2012;104(1):41-59. Available from: https://doi.org/10.1093/bmb/lds032
9. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14. Available from: https://cancerimmunity.org/journal/view.php?aid=120114
10. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287. Available from: https://doi.org/10.1038/nrc3236
11. Little M. Generation, structure, and function of antibodies. In: Little M, editor. Antibodies for Treating Cancer: Basics, Development, and Applications. Cham: Springer International Publishing; 2021. p. 35-46. Available from: https://doi.org/10.1007/978-3-030-80413-8_2
12. Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302. Available from: https://doi.org/10.3389/fimmu.2013.00302
13. Megha KB, Mohanan PV. Role of immunoglobulin and antibodies in disease management. Int J Biol Macromol. 2021;169:28-38. Available from: https://doi.org/10.1016/j.ijbiomac.2020.12.073
14. Román VRG, Murray JC, Weiner LM. Antibody-dependent cellular cytotoxicity (ADCC). In: Weiner LM, editor. Antibody Fc. London: Academic Press; 2014. p. 1-27. Available from: https://doi.org/10.1016/B978-0-12-394802-1.00001-3
15. Frenzel A, Kügler J, Helmsing S, Meier D, Schirrmann T, Hust M, et al. Designing human antibodies by phage display. Transfus Med Hemother. 2017;44(5):312-318. Available from: https://doi.org/10.1159/000479633
16. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. Available from: https://doi.org/10.1186/s12929-019-0592-z
17. Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, et al. Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol. 2020;11:1986. Available from: https://doi.org/10.3389/fimmu.2020.01986
18. Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH. Basics of antibody phage display technology. Toxins (Basel). 2018;10(6):236. Available from: https://doi.org/10.3390/toxins10060236
19. Almagro JC, Pedraza-Escalona M, Arrieta HI, Pérez-Tapia SM. Phage display libraries for antibody therapeutic discovery and development. Antibodies (Basel). 2019;8(3):44. Available from: https://doi.org/10.3390/antib8030044
20. Valldorf B, Hinz SC, Russo G, Pekar L, Mohr L, Klemm J, et al. Antibody display technologies: selecting the cream of the crop. Biol Chem. 2022;403(5-6):455-477. Available from: https://doi.org/10.1515/hsz-2020-0382
21. Carbone F, Russo C, Colamatteo A, La Rocca C, Fusco C, Matarese A, et al. Cellular and molecular signaling towards T-cell immunological self-tolerance. J Biol Chem. 2024;300(4):107134. Available from: https://doi.org/10.1016/j.jbc.2024.107134
22. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Res Pharm Chem. 2012;2(2):636-649. Available from: https://www.ijrpc.com/files/12-2108.pdf
23. Girish CH, Vijayalakshmi P, Mentham R, Rao CB, Nama S. A review on breast cancer. Int J Pharma Bio Sci. 2014;4(2):47-54.
24. Rani TT, Brahmaiah B, Revathi B, Nama S, Chandu BR. Targeting of anticancer drugs through nanoparticles. Int J Pharm Ther. 2013;4(3):154-159. Available from: http://www.ijptjournal.com/abstract/targeting-of-anti-cancer-drugs-through-nanoparticles-224.html
25. Pisipati SVV, Pathapati H, Bhukya G, Nuthakki S, Chandu BR, Nama S, et al. Lycopene: redress for prostate cancer. 2013. Available from: https://www.academia.edu/75895370/Lycopene_Redress_for_prostate_cancer
26. Vennela B, Shirisha V, Rao CB, Gullapalli V, Batsala M. Current and future strategies for therapy of pancreatic cancer. Int J Res Pharm Chem. 2012;2(3):728-740. Available from: https://www.ijrpc.com/files/24-2114.pdf